These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 3290717)
1. Clinical experience with COP-1 in multiple sclerosis. Bornstein MB; Miller A; Slagle S; Weitzman M; Crystal H; Drexler E; Keilson M; Merriam A; Wassertheil-Smoller S; Spada V Neurology; 1988 Jul; 38(7 Suppl 2):66-9. PubMed ID: 3290717 [TBL] [Abstract][Full Text] [Related]
2. Suppression of experimental allergic encephalomyelitis by COP1--relevance to multiple sclerosis. Arnon R; Teitelbaum D; Sela M Isr J Med Sci; 1989 Dec; 25(12):686-9. PubMed ID: 2533187 [TBL] [Abstract][Full Text] [Related]
3. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. Bornstein MB; Miller A; Slagle S; Weitzman M; Crystal H; Drexler E; Keilson M; Merriam A; Wassertheil-Smoller S; Spada V N Engl J Med; 1987 Aug; 317(7):408-14. PubMed ID: 3302705 [TBL] [Abstract][Full Text] [Related]
5. Induction of recurrent experimental allergic encephalomyelitis with myelin basic protein. Panitch H; Ciccone C Ann Neurol; 1981 May; 9(5):433-8. PubMed ID: 6168235 [TBL] [Abstract][Full Text] [Related]
6. [Clinical trial of copolymer 1 in multiple sclerosis]. Teitelbaum D; Arnon R; Sela M; Abramsky O Harefuah; 1989 May; 116(9):453-6. PubMed ID: 2680816 [TBL] [Abstract][Full Text] [Related]
7. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Fontoura P; Garren H; Steinman L Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989 [TBL] [Abstract][Full Text] [Related]
8. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Steinman L; Zamvil SS Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891 [TBL] [Abstract][Full Text] [Related]
9. Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. Fassas A; Kimiskidis VK J Neurol Sci; 2004 Aug; 223(1):53-8. PubMed ID: 15261561 [TBL] [Abstract][Full Text] [Related]
10. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting. Stinissen P; Raus J Acta Neurol Belg; 1999 Mar; 99(1):65-9. PubMed ID: 10218096 [TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures. Karussis D; Slavin S J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562 [TBL] [Abstract][Full Text] [Related]
12. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803 [TBL] [Abstract][Full Text] [Related]
13. Cop 1 as a candidate drug for multiple sclerosis. Teitelbaum D; Arnon R; Sela M J Neural Transm Suppl; 1997; 49():85-91. PubMed ID: 9266417 [TBL] [Abstract][Full Text] [Related]
15. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a rat model of experimental autoimmune encephalomyelitis with human MBP as antigen. Guo L; Li Y; Lin H; Ji X; Li J; Que L; Zhang Y; Rong Y; Wang J Cell Mol Immunol; 2004 Oct; 1(5):387-91. PubMed ID: 16285900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]